About the ABPI

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

You can find the 2020 HCP/HCO data and the new patient organisation gateway on Disclosure UK by visiting - www.disclosureuk.org.uk.

Any company that abides by the ABPI Code that has not provided a link for the gateway but would like to, please contact the ABPI – info@disclosureuk.org.uk.

The 2020 HCP/HCO data can be broken down in the following chart:

Values for research and development (R&D) are always published in aggregate. Values for non-R&D collaborations are broken-down and published against individually named HCPs and HCOs, where data protection law allows.


Presenting results based on 2020 data as of 23 June 2021 to allow time for analysis. Numbers can be updated over time.

Total categories

2020 value

2019 value

What was the total transfer of value disclosed for 2020

£487.8 million

£542.9 million

How much did the industry spend on R&D collaborations with HCPs and HCOs?

£348.9 million

£381.9 million

What percentage change was there in R&D spend vs. the previous year?

- 8.64%

+ 1.21% 

How much was spent on HCPs and HCOs for non-R&D collaborations

£138.9 million

£160.9 million

How much of the non-R&D value was against a named person or organisation?

£129.8 million

£139.0 million

What percentage of the non-R&D value is disclosed against a named person or organisation?



Estimated percentage of HCPs who agreed to be named for non-R&D spend



How much was spent on the following for non-R&D collaborations:


·         Registration fees

£1.9 million

£3.6 million

·         Sponsorship agreements with HCOs/3rd parties

£24.5 million

£34.1 million

·         Travel and accommodation

£1.5 million

£10.4 million

·         Donations and grants to HCOs

£53.0 million

£44.2 million

·         Fees

£52.0 million

£56.6 million

·         Related expenses agreed in the fee for services or consultancy contract

£2.2 million

£7.5 million

·         Joint working

£3.9 million

£4.6 million

How many companies disclosed 2020 data



*As defined in the ABPI Code of Practice, pharmaceutical companies must disclose their spend in individual categories. The following are some examples of what each category includes.

R&D spend includes:

Transfers of value to health professionals or healthcare organisations related to the planning or conduct of:

  • non-clinical studies (as defined in the OECD Principles of Good Laboratory Practice)
  • clinical trials (as defined in Directive 2001/20/EC)
  • non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of, individual or groups of health professionals specifically for the study
  • costs that are subsidiary to these activities are also included.

Non-R&D spend includes:

More information in How we work with HCPs and How we work with HCOs.

  • Registration fees – e.g. a company paying for an HCP to attend a medical conference for education and training.
  • Sponsorship agreements with HCOs/3rd parties – e.g. a company may fund a third party to run a training seminar.
  • Travel and accommodation – e.g. paying for the flights or rail fares for a HCP to attend a conference.
  • Donations and grants to HCOs – e.g. buying equipment for HCOs, such as medical equipment, books, or products which support disaster relief.
  • Fees – e.g. paying HCPs for their time to sit on advisory boards and help with the development of medicines.
  • Related expenses agreed in the fee for services or consultancy contract – e.g. travel and accommodation requirements to support a HCP deliver the work they were contracted to do for a pharmaceutical company.
  • ‘Joint Working’ means formal arrangements between the NHS and one or more pharmaceutical companies where all parties make a contribution, and the outcomes are measured.



Media enquiries

+44 (0) 20 7747 7147​​